TABMELT® Granted Patent Rights in Russia, Expanding Vivera Global Licensing
NEWPORT BEACH, Calif., Feb. 25, 2021 /PRNewswire/ — Vivera Pharmaceuticals, Inc., is pleased to announce the expansion of its exclusive global licensing of the novel
Vivera Pharmaceuticals and Burkhan Group Announce New COVID-19 Testing Initiative
NEWPORT BEACH, Calif., Jan. 25, 2021 /PRNewswire/ — Vivera Pharmaceuticals, in partnership with Burkhan Group, is excited to announce a new testing initiative in Southern
Vivera Pharmaceuticals Announces $440 Million in Backing by JR Dallas Wealth Management
NEWPORT BEACH, Calif., Nov. 25, 2020 /PRNewswire/ — Vivera Pharmaceuticals and Burkhan World today announce financial backing by JR Dallas Wealth Management in support of
Vivera Pharmaceuticals Welcomes Gerald A. Maguire, MD to Advisory Board
NEWPORT BEACH, Calif., Nov. 24, 2020 /PRNewswire/ — Vivera Pharmaceuticals is pleased to announce the appointment of Dr. Gerald A. Maguire, Professor and Chair of
Vivera Pharmaceuticals Partners with EcoGroup USA in the Distribution of its BioZone Sanitizing Stations
NEWPORT BEACH, Calif., Nov. 18, 2020 /PRNewswire/ — Vivera Pharmaceuticals is excited to announce a distribution partnership with EcoGroup USA for Vivera’s BioZone, an advanced
Vivera Pharmaceuticals Selected to Screen Travellers to the UAE for COVID-19
NEWPORT BEACH, Calif., Oct. 7, 2020 /PRNewswire/ — Vivera Pharmaceuticals has been selected by Pure Health, the largest laboratory network in the UAE, to test
Investor Relations and Media Inquiries:
Investor Inquiries:
[email protected]
Media Inquiries:
[email protected]
Forward-looking and cautionary statements:
Statements made on our website may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera’s future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera’s expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera, reference should be made to Vivera’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera’s CSE Listing Statement. The forward-looking information contained on our website is made as of the date of the release of such statement and Vivera does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents on our site.
